Longduoduo Company Limited (LDDD) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist Longduoduo Company Limited (LDDD) ein Healthcare-Unternehmen mit einer Bewertung von 0. Die Aktie erzielt 51/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 15. März 2026Longduoduo Company Limited (LDDD) Gesundheitswesen & Pipeline-Uebersicht
Longduoduo Company Limited delivers preventive healthcare solutions in China, addressing cardiovascular and cerebrovascular diseases. Their services encompass disease screening, treatments, and healthcare products distributed via third-party channels. Operating in the diagnostics and research segment, the company caters to a growing demand for preventive care in the Chinese market.
Investmentthese
Longduoduo Company Limited presents a speculative investment opportunity within the Chinese preventive healthcare market. The company's focus on cardiovascular and cerebrovascular disease prevention aligns with growing health concerns and government support for proactive healthcare measures. However, the company's negative P/E ratio of -51.82 and negative profit margin of -10.9% indicate financial challenges. The high gross margin of 98.5% suggests potential for profitability if operational efficiencies improve. Key growth catalysts include expanding service offerings and penetrating new geographic regions within China. Investors should carefully consider the risks associated with investing in a small-cap OTC-listed company with limited financial history.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $0.02 billion indicates a small-cap company with potential for high growth but also higher risk.
- Negative P/E ratio of -51.82 reflects current unprofitability, requiring careful monitoring of future earnings.
- High gross margin of 98.5% suggests strong pricing power or a focus on high-value services.
- Beta of 1.53 indicates higher volatility compared to the overall market.
- No dividend yield reflects a focus on reinvesting earnings for growth.
Wettbewerber & Vergleichsunternehmen
Staerken
- Specialized focus on cardiovascular and cerebrovascular disease prevention.
- Comprehensive range of preventive healthcare services and products.
- Established network of third-party healthcare providers and sales agents.
- Innovative treatment offerings such as meridian-regulating iatrotechnics.
Schwaechen
- Limited operating history as the company was founded in 2020.
- Negative P/E ratio and profit margin indicate financial challenges.
- Small market capitalization and OTC listing increase investment risk.
- Dependence on third-party providers and sales agents.
Katalysatoren
- Upcoming: Potential partnerships with hospitals and clinics to expand service reach.
- Ongoing: Expansion of service offerings to include new preventive healthcare treatments.
- Ongoing: Development and launch of new healthcare products.
- Ongoing: Leveraging telemedicine and digital health platforms to improve patient engagement.
Risiken
- Potential: Intense competition from established healthcare providers in China.
- Potential: Changes in government regulations and healthcare policies could impact the company's operations.
- Potential: Economic slowdown in China could reduce demand for preventive healthcare services.
- Ongoing: Limited financial disclosure increases investment risk.
- Ongoing: Low trading volume and liquidity can lead to price volatility.
Wachstumschancen
- Expansion into New Geographic Regions: Longduoduo can expand its services to other regions within China, targeting areas with high prevalence of cardiovascular and cerebrovascular diseases. The Chinese healthcare market is vast, offering significant growth potential for companies that can effectively penetrate new regions. This expansion could involve establishing new partnerships with local healthcare providers and sales agents. Timeline: Ongoing.
- Development of New Preventive Healthcare Products: Longduoduo can invest in research and development to create new preventive healthcare products that complement its existing service offerings. These products could include dietary supplements, medical devices, or digital health solutions. The market for preventive healthcare products is growing rapidly, driven by increasing consumer awareness and demand for proactive health management. Timeline: Ongoing.
- Strategic Partnerships with Hospitals and Clinics: Forming strategic partnerships with hospitals and clinics can provide Longduoduo with access to a wider patient base and enhance its credibility. These partnerships can involve offering Longduoduo's services within the hospital or clinic setting, or co-developing new preventive healthcare programs. The hospital and clinic market in China is large and fragmented, offering numerous partnership opportunities. Timeline: Ongoing.
- Leveraging Telemedicine and Digital Health Platforms: Longduoduo can leverage telemedicine and digital health platforms to expand its reach and improve patient engagement. This can involve offering online consultations, remote monitoring, and personalized health coaching. The digital health market in China is growing rapidly, driven by increasing internet penetration and the adoption of mobile health technologies. Timeline: Ongoing.
- Focus on Personalized Healthcare Solutions: Tailoring preventive healthcare solutions to individual patient needs can improve outcomes and enhance patient satisfaction. This can involve using genetic testing, lifestyle assessments, and other data to develop personalized treatment plans. The market for personalized healthcare is growing, driven by advances in genomics and data analytics. Timeline: Ongoing.
Chancen
- Expansion into new geographic regions within China.
- Development of new preventive healthcare products and services.
- Strategic partnerships with hospitals and clinics.
- Leveraging telemedicine and digital health platforms.
Risiken
- Intense competition from established healthcare providers.
- Changes in government regulations and healthcare policies.
- Economic slowdown in China.
- Potential for product liability claims.
Wettbewerbsvorteile
- Specialized treatment offerings like meridian-regulating iatrotechnics and double blood purification.
- Focus on the specific market of cardiovascular and cerebrovascular disease prevention in China.
- Established network of third-party healthcare service providers and sales agents.
- Proprietary healthcare products and treatment protocols.
Ueber LDDD
Founded in 2020 and headquartered in Hohhot, China, Longduoduo Company Limited operates within the preventive healthcare sector, focusing on solutions for cardiovascular and cerebrovascular diseases. The company's inception was driven by the increasing prevalence of these conditions in China and the growing demand for proactive healthcare measures. Longduoduo offers a suite of preventive healthcare services, including disease screening, healthcare treatments, and healthcare products. These services are designed to mitigate the risks associated with myocardial infarction, cerebral infarction, hemiplegia, and other related conditions. The company utilizes a network of third-party healthcare service providers, product suppliers, and sales agents to deliver its offerings to the market. Longduoduo's service portfolio includes specialized treatments such as meridian-regulating and consciousness restoring iatrotechnics, double blood purification, immunological ozonated autohemotherapy, platelet-rich plasma, relaxation therapy, vegetative nerve regulation, and microwave therapy. These diverse therapeutic approaches aim to provide comprehensive preventive care to its clientele. While a relatively young company, Longduoduo is strategically positioned to capitalize on the expanding healthcare market in China, driven by increasing health awareness and government initiatives promoting preventive care.
Was das Unternehmen tut
- Provides disease screening services for early detection of health risks.
- Offers healthcare treatments focused on preventing cardiovascular and cerebrovascular diseases.
- Distributes healthcare products designed to promote overall wellness and disease prevention.
- Delivers meridian-regulating and consciousness restoring iatrotechnics.
- Offers double blood purification services.
- Provides immunological ozonated autohemotherapy.
- Administers platelet-rich plasma therapy.
- Offers relaxation therapy, vegetative nerve regulation, and microwave therapy.
Geschaeftsmodell
- Generates revenue through the provision of preventive healthcare services.
- Sells healthcare products through third-party distributors and sales agents.
- Partners with healthcare providers to offer services within their facilities.
- Focuses on preventing myocardial infarction, cerebral infarction, hemiplegia, and cardiovascular and cerebrovascular diseases.
Branchenkontext
Longduoduo Company Limited operates in the growing Chinese healthcare market, specifically within the preventive healthcare segment. The demand for preventive care is increasing due to rising healthcare awareness and government initiatives promoting early disease detection and management. The market is competitive, with established players and emerging companies offering various preventive healthcare solutions. Longduoduo differentiates itself through its specialized treatments and focus on cardiovascular and cerebrovascular diseases. The company's success depends on its ability to effectively market its services, establish strong partnerships, and maintain high-quality standards.
Wichtige Kunden
- Individuals seeking preventive healthcare solutions in China.
- Patients at risk of cardiovascular and cerebrovascular diseases.
- Healthcare providers who partner with Longduoduo to offer preventive services.
- Consumers interested in purchasing healthcare products for disease prevention.
Finanzdaten
Chart & Info
Longduoduo Company Limited (LDDD) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer LDDD verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer LDDD.
Kursziele
Wall-Street-Kurszielanalyse fuer LDDD.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von LDDD auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Wettbewerber & Vergleichsunternehmen
Fuehrung: Hongxiao Zhou
CEO
Hongxiao Zhou is the CEO of Longduoduo Company Limited, leading a team of 52 employees. His background includes experience in the healthcare sector, with a focus on preventive care and disease management. Prior to joining Longduoduo, Zhou held various leadership positions in healthcare companies, where he was responsible for developing and implementing strategic initiatives. He has a strong understanding of the Chinese healthcare market and the challenges and opportunities it presents. Zhou is committed to driving Longduoduo's growth and success by providing innovative and effective preventive healthcare solutions.
Erfolgsbilanz: Since founding Longduoduo in 2020, Hongxiao Zhou has focused on establishing the company's presence in the Chinese preventive healthcare market. Key milestones under his leadership include developing a comprehensive range of preventive healthcare services and products, establishing a network of third-party healthcare providers and sales agents, and securing partnerships with key stakeholders in the healthcare industry. Zhou's strategic decisions have positioned Longduoduo for future growth and success.
LDDD OTC-Marktinformationen
The OTC Other tier, also known as the Pink tier, represents the most speculative and least regulated segment of the OTC market. Companies in this tier often have limited financial disclosure, may be distressed, or may not meet the minimum requirements for higher OTC tiers like OTCQB or OTCQX. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like the NYSE or NASDAQ. These companies may not be current in their reporting requirements.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases the risk of investing in LDDD.
- Low trading volume and liquidity can lead to price volatility.
- OTC Other tier listing indicates a higher level of risk compared to stocks listed on major exchanges.
- Potential for fraud or manipulation due to the lack of regulatory oversight.
- Uncertainty regarding the company's long-term viability and financial stability.
- Verify the company's registration and legal standing.
- Attempt to obtain and review any available financial statements.
- Assess the company's management team and their track record.
- Research the company's industry and competitive landscape.
- Understand the company's business model and revenue streams.
- Evaluate the risks associated with investing in an OTC-listed company.
- Consult with a financial advisor before making any investment decisions.
- Company has been in operation since 2020.
- Focus on preventive healthcare solutions aligns with growing market demand.
- Presence of a CEO and management team.
- Company has 52 employees.
Haeufige Fragen zu LDDD
What are the key factors to evaluate for LDDD?
Longduoduo Company Limited (LDDD) currently holds an AI score of 51/100, indicating moderate score. Key strength: Specialized focus on cardiovascular and cerebrovascular disease prevention.. Primary risk to monitor: Potential: Intense competition from established healthcare providers in China.. This is not financial advice.
How frequently does LDDD data refresh on this page?
LDDD prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven LDDD's recent stock price performance?
Recent price movement in Longduoduo Company Limited (LDDD) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized focus on cardiovascular and cerebrovascular disease prevention.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider LDDD overvalued or undervalued right now?
Determining whether Longduoduo Company Limited (LDDD) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying LDDD?
Before investing in Longduoduo Company Limited (LDDD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding LDDD to a portfolio?
Potential reasons to consider Longduoduo Company Limited (LDDD) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Specialized focus on cardiovascular and cerebrovascular disease prevention.. Additionally: Comprehensive range of preventive healthcare services and products.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of LDDD?
Yes, most major brokerages offer fractional shares of Longduoduo Company Limited (LDDD) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track LDDD's earnings and financial reports?
Longduoduo Company Limited (LDDD) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for LDDD earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available company data and may be limited due to the company's OTC listing and disclosure status.
- AI analysis pending for LDDD.